By Nicky Forster, AP News, April 5, 2024 The 2023-24 respiratory virus season is ebbing as viral activity from flu, COVID-19 and RSV falls across most of the U.S. Here’s the situation in four charts: How active are the respiratory …
FDA authorizes COVID drug Pemgarda for high-risk patients
By Carrie Macmillian, Yale Medicine, April 5, 2024 The Food and Drug Administration (FDA) granted an emergency use authorization (EUA) to a medicine meant to protect certain immunocompromised people against COVID-19. The medicine, pemivibart (brand name Pemgarda™), is for people …
No increased stroke risk after COVID-19 bivalent vaccine
Batya Swift Yasgur, Medscape, March 28, 2024 Receipt of the bivalent COVID-19 vaccine was not associated with an increased stroke risk in the first 6 weeks after vaccination with either the Pfizer or Moderna vaccines, a new study of Medicare …
COVID-19 variant update
CDC, March 26, 2024 As of March 26, 2024, the SARS-CoV-2 Omicron variant JN.1 has very high prevalence in the United States, with CDC Nowcast projections estimating JN.1 to account for more than 95% of all COVID-19 illnesses in the US. The …
13 things to know about Paxlovid, the latest COVID-19 pill
Kathy Katella, Yale Medicine, March 25, 2024 Paxlovid, an oral antiviral pill that can be taken at home, is the go-to treatment for COVID-19. If you are at high risk for severe disease from COVID, and you take it within the …